Dermatology
Cicatricial Alopecia
12
Pipeline Programs↗
2
Active Trials↗
4
Companies Involved↗
Cicatricial Alopecia is an emerging landscape with 12 programs across 4 companies. The most active players are LEO Pharma, Alnylam Pharmaceuticals, Amgen. 6 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 13
Phase 3
No programs
Analysis
Trial Status
6
clinical trials
Completed3 · 50%
Withdrawn1 · 17%
Recruiting1 · 17%
Not yet recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia
Not yet recruiting·—·Phase 4·NCT06998433·56 enrolled
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Completed·—·Phase 2·NCT05076006·50 enrolled
Ritlecitinib for Cicatricial Alopecia
Completed·—·Phase 2·NCT05549934·50 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)